NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $17.02 -0.02 (-0.12%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$17.02 +0.00 (+0.03%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Theravance Biopharma Stock (NASDAQ:TBPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theravance Biopharma alerts:Sign Up Key Stats Today's Range$17.02▼$17.0550-Day Range$16.81▼$17.0852-Week Range$13.08▼$21.03Volume683,739 shsAverage Volume377,351 shsMarket Capitalization$883.68 millionP/E Ratio16.85Dividend YieldN/APrice Target$19.40Consensus RatingHold Company Overview Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients. Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults. YUPELRI is commercialized in the United States through a collaboration with Viatris. Theravance Biopharma also maintains research and development programs focused on respiratory and immunology applications. The company was established in 2013 following the separation of the biopharmaceutical operations of Theravance, Inc. It is headquartered in Dublin, Ireland, with additional operations in the United States. Theravance Biopharma is led by Rick E. Winningham, who serves as chief executive officer and chairman.AI Generated. May Contain Errors. Read More Theravance Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreTBPH MarketRank™: Theravance Biopharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 252nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 8 hold ratings, and no sell ratings.Upside PotentialTheravance Biopharma has a consensus price target of $19.40, representing about 14.0% upside from its current price of $17.02.Amount of Analyst CoverageTheravance Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Theravance Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-48.08% Earnings GrowthEarnings for Theravance Biopharma are expected to decrease by -48.08% in the coming year, from $1.56 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is 16.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is 16.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.38% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 4.54.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 5.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.77 News SentimentTheravance Biopharma has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TBPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,016,830.00 in company stock.Percentage Held by Insiders7.65% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBPH Stock News HeadlinesZymeworks' Theravance Deal Is A Breath Of Fresh Cash FlowSeptember 18 at 3:42 PM | seekingalpha.comTheravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 SharesSeptember 18 at 7:07 AM | insidertrades.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio. | Stansberry Research (Ad)Theravance Biopharma IncAugust 20, 2026 | money.usnews.comTBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its ShareholdersAugust 15, 2026 | businesswire.comTheravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 10, 2026 | prnewswire.comZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | financialpost.comFTheravance Biopharma Stock Dividends | NASDAQ:TBPH | BenzingaJuly 13, 2026 | benzinga.comSee More Headlines TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $18.71 on January 1st, 2026. Since then, TBPH stock has decreased by 9.0% and is now trading at $17.02. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.18. The biopharmaceutical company had revenue of $20.73 million for the quarter, compared to analysts' expectations of $22.49 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 0.77% and a net margin of 51.58%. Who are Theravance Biopharma's major shareholders? Theravance Biopharma's top institutional shareholders include Newtyn Management LLC (6.61%), Wedge Capital Management L L P NC (0.25%), Wellington Management Group LLP (0.22%) and Engineers Gate Manager LP (0.19%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/10/2026Today9/19/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TBPH's financial health is in the Red zone, according to TradeSmith. TBPH has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees90Year Founded1996Price Target and Rating Average Price Target for Theravance Biopharma$19.40 High Price Target$27.00 Low Price Target$15.00 Potential Upside/Downside+14.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.01 Trailing P/E Ratio16.85 Forward P/E Ratio10.91 P/E GrowthN/ANet Income$105.89 million Net Margins51.58% Pretax Margin56.48% Return on Equity-0.77% Return on Assets-0.46% Debt Debt-to-Equity RatioN/A Current Ratio13.54 Quick Ratio13.54 Sales & Book Value Annual Sales$107.46 million Price / Sales8.22 Cash FlowN/A Price / Cash FlowN/A Book Value$5.86 per share Price / Book2.90Miscellaneous Outstanding Shares51,920,000Free Float47,947,000Market Cap$883.68 million OptionableOptionable Beta0.25 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TBPH) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
